IP Library Granted Patent US 12,109,176
Granted Patent B1
US 12,109,176 · App. 18/304,192 · Granted Oct 8, 2024

Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives

Inventor: Thomas Bryan (Marina, CA)
A61K31/047A61K31/198A61K45/06A61P31/04A61P31/10C02F1/50C02F2303/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,109,176
App. No.
18/304,192
Granted
Oct 8, 2024
Kind
B1
Abstract

A method of desensitizing microbes to pro-biofilm amino acids and amino acid derivatives in plasma comprising administering a sufficient amount of glycerol. A method of sensitizing microbes to anti-biofilm amino acids and amino acid derivatives in plasma comprising administering a sufficient amount of glycerol. Methods of increasing a plasma concentration of glycerol comprising administering a sufficient amount of glycerol. A method of treating an infection and/or contamination comprising applying glycerol and anti-biofilm amino acids and/or amino acid derivatives to a surface to be treated and/or water to be treated. A method of treating a biofilm producing viral infection comprising administering a sufficient, non-toxic concentration of glycerol. A method of treating a protozoal infection comprising administering a sufficient, non-toxic concentration of glycerol. A method of treating a hybrid infection comprising administering a sufficient, non-toxic concentration of glycerol and anti-biofilm amino acids and/or amino acid derivatives.

Claims (5)

1. A method of desensitizing microbes to pro-biofilm amino acids and amino acid derivatives in plasma comprising administering a solution comprising a sufficient, non-toxic concentration of glycerol, wherein glycerol is the sole therapeutic agent.

2. The method of claim 1 , wherein the step of administering comprises administering to a wound the solution.

3. The method of claim 1 , wherein the step of administering comprises administering the solution vaginally, rectally, orally, intravenously, intra-arterially, intracavernously, intrathecally, and/or topically.

4. The method of claim 1 , wherein 1.7 to 4.3 g/h of glycerol are administered intravenously and/or intra-arterially.

5. The method of claim 1 , further comprising the step of administering at least one antimicrobial.